<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00971685</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-2008-002</org_study_id>
    <nct_id>NCT00971685</nct_id>
  </id_info>
  <brief_title>The Treatment of Lenalidomide in Patients With POEMS Syndrome</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Lenalidomide (RevlimidÂ®) in Patients With POEMS Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istituto Clinico Humanitas</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lenalidomide is a immunomodulatory drug derived from thalidomide, without neurotoxicity.
      Lenalidomide blocks the increased secretion of interleukin-6, tumor necrosis factor alpha and
      vascular endothelial growth factor (VEGF). The association with dexamethasone increased
      Lenalidomide response rate.

      More recently the efficacy of Lenalidomide has been reported in a patient with POEMS
      (POEMS:polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes)
      syndrome with improvement of clinical condition and reduction of vascular endothelial growth
      factor (VEGF) and interleukin-6 (IL-6) level.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2011</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of clinical efficacy of Lenalidomide for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg)) in patients with POEMS syndrome after 6 cycles.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and the activity.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>POEMS Syndrome</condition>
  <arm_group>
    <arm_group_label>Lenalidomide plus Dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide and dexamethasone</intervention_name>
    <description>RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).</description>
    <arm_group_label>Lenalidomide plus Dexamethasone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with a diagnosis of POEMS syndrome based on published diagnostic criteria

        Exclusion Criteria:

          -  Any serious medical condition, laboratory abnormality, or psychiatric illness that
             would prevent the subject from signing the informed consent form
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Armando Santoro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Clinico Humanitas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Armando Santoro, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>4080</phone_ext>
    <email>armando.santoro@humanitas.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andrea Nozza, MD</last_name>
    <phone>+39028224</phone>
    <phone_ext>4080</phone_ext>
    <email>andrea.nozza@humanitas.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Istituto Clinco Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Nozza, MD</last_name>
      <phone>+39028224</phone>
      <phone_ext>4080</phone_ext>
      <email>andrea.nozza@humanitas.it</email>
    </contact>
    <investigator>
      <last_name>Andrea Nozza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>September 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>September 1, 2010</last_update_submitted>
  <last_update_submitted_qc>September 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Armando Santoro, MD</name_title>
    <organization>Istituto Clinico Humanitas</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>POEMS Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

